Published in Int J Radiat Oncol Biol Phys on February 01, 2005
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys (2010) 2.84
Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys (2010) 1.78
Gastrointestinal radiation injury: symptoms, risk factors and mechanisms. World J Gastroenterol (2013) 1.06
Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys (2012) 1.00
Esophagitis, treatment-related toxicity in non-small cell lung cancer. Rev Recent Clin Trials (2012) 0.93
Modeling the risk of radiation-induced acute esophagitis for combined Washington University and RTOG trial 93-11 lung cancer patients. Int J Radiat Oncol Biol Phys (2011) 0.93
Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid). Radiat Oncol (2015) 0.89
Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer. Radiat Oncol (2007) 0.85
Factors affecting the success of endoscopic bougia dilatation of radiation-induced esophageal stricture. Dig Dis Sci (2011) 0.84
Improving target coverage and organ-at-risk sparing in intensity-modulated radiotherapy for cervical oesophageal cancer using a simple optimisation method. PLoS One (2015) 0.82
Mean esophageal radiation dose is predictive of the grade of acute esophagitis in lung cancer patients treated with concurrent radiotherapy and chemotherapy. J Radiat Res (2012) 0.82
Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor? Strahlenther Onkol (2012) 0.80
A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. J Thorac Dis (2016) 0.80
Amphotericin B lozengers: prophylaxis for esophagitis in thoracic radiotherapy: a prospective study. Strahlenther Onkol (2009) 0.79
Motion of the esophagus due to cardiac motion. PLoS One (2014) 0.78
A patient with tracheoesophageal fistula and esophageal cancer after radiotherapy. Nat Rev Gastroenterol Hepatol (2010) 0.75
Dosimetric evaluation of the feasibility of stereotactic body radiotherapy for primary lung cancer with lobe-specific selective elective nodal irradiation. J Radiat Res (2015) 0.75
Radiation-induced esophagitis in lung cancer. Lung Cancer (Auckl) (2016) 0.75
Independent test of a model to predict severe acute esophagitis. Adv Radiat Oncol (2016) 0.75
Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer. Cancers (Basel) (2017) 0.75
InterPro: the integrative protein signature database. Nucleic Acids Res (2008) 25.07
The InterPro Database, 2003 brings increased coverage and new features. Nucleic Acids Res (2003) 24.72
InterPro, progress and status in 2005. Nucleic Acids Res (2005) 17.53
InterPro in 2011: new developments in the family and domain prediction database. Nucleic Acids Res (2011) 13.45
New developments in the InterPro database. Nucleic Acids Res (2007) 12.49
Genome duplication in the teleost fish Tetraodon nigroviridis reveals the early vertebrate proto-karyotype. Nature (2004) 11.03
The ProDom database of protein domain families: more emphasis on 3D. Nucleic Acids Res (2005) 7.66
ProDom: automated clustering of homologous domains. Brief Bioinform (2002) 7.42
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol (2008) 7.01
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Enzyme-specific profiles for genome annotation: PRIAM. Nucleic Acids Res (2003) 5.10
MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity (2010) 4.65
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol (2007) 4.32
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009) 3.91
Genetic regulation of biological nitrogen fixation. Nat Rev Microbiol (2004) 3.01
Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 2.94
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA (2007) 2.84
How long have I had my cancer, doctor? Estimating tumor age via Collins' law. Oncology (Williston Park) (2011) 2.84
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys (2012) 2.80
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol (2008) 2.74
The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys (2005) 2.70
Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA (2008) 2.67
Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys (2010) 2.66
InterPro: an integrated documentation resource for protein families, domains and functional sites. Brief Bioinform (2002) 2.66
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol (2009) 2.41
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
Prone positioning causes the heart to be displaced anteriorly within the thorax: implications for breast cancer treatment. Int J Radiat Oncol Biol Phys (2008) 2.39
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys (2010) 2.32
Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study. Int J Radiat Oncol Biol Phys (2009) 2.27
The relationship among gene expression, the evolution of gene dosage, and the rate of protein evolution. PLoS Genet (2010) 2.20
Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys (2010) 2.14
Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer (2009) 2.08
Global changes in gene expression in Sinorhizobium meliloti 1021 under microoxic and symbiotic conditions. Mol Plant Microbe Interact (2004) 2.04
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
Exploring root symbiotic programs in the model legume Medicago truncatula using EST analysis. Nucleic Acids Res (2002) 1.99
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol (2006) 1.94
The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol (2008) 1.93
Radiation-induced lung injury. Semin Radiat Oncol (2003) 1.82
Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys (2010) 1.78
Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J (2006) 1.76
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg (2009) 1.76
Assessment of the residual error in soft tissue setup in patients undergoing partial breast irradiation: results of a prospective study using cone-beam computed tomography. Int J Radiat Oncol Biol Phys (2007) 1.73
Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys (2010) 1.72
The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys (2010) 1.65
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol (2006) 1.65
Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys (2005) 1.64
Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. Int J Radiat Oncol Biol Phys (2007) 1.61
One to three versus four or more positive nodes and postmastectomy radiotherapy: time to end the debate. J Clin Oncol (2008) 1.54
Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol (2004) 1.50
Point: Hyperthermia with radiation for chest wall recurrences. J Natl Compr Canc Netw (2007) 1.49
Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys (2003) 1.49
BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res (2011) 1.49
Predicting radiotherapy-induced cardiac perfusion defects. Med Phys (2005) 1.47
Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer (2005) 1.47
Transcriptional programming and functional interactions within the Phytophthora sojae RXLR effector repertoire. Plant Cell (2011) 1.47
The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM. Med Phys (2012) 1.46
Comparing radical prostatectomy and brachytherapy for localized prostate cancer. Oncology (Williston Park) (2004) 1.46
Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture. Int J Radiat Oncol Biol Phys (2010) 1.44
Radiation-induced lung injury. Assessment, management, and prevention. Oncology (Williston Park) (2008) 1.44
Normal tissue effects: reporting and analysis. Semin Radiat Oncol (2003) 1.44
Self-consistent tumor control probability and normal tissue complication probability models based on generalized EUD. Med Phys (2007) 1.40
Elective nodal irradiation for locally advanced non-small-cell lung cancer: it's called cancer for a reason. Int J Radiat Oncol Biol Phys (2009) 1.38
Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.36
Challenges in defining radiation pneumonitis in patients with lung cancer. Int J Radiat Oncol Biol Phys (2005) 1.33
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis (2013) 1.31
Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys (2010) 1.31
Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys (2010) 1.30
Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys (2013) 1.29
Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution. Int J Radiat Oncol Biol Phys (2003) 1.28
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26
A methodology for using SPECT to reduce intensity-modulated radiation therapy (IMRT) dose to functioning lung. Int J Radiat Oncol Biol Phys (2006) 1.24
An environmental perspective on metabolism. J Theor Biol (2007) 1.21
Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res (2004) 1.21
ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One (2012) 1.21
Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. Cancer (2010) 1.14
Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol Phys (2002) 1.14
RBCs labeled at two biotin densities permit simultaneous and repeated measurements of circulating RBC volume. Transfusion (2004) 1.13
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol (2005) 1.12
A dose-volume-based tool for evaluating and ranking IMRT treatment plans. J Appl Clin Med Phys (2004) 1.12
Decreased expression of updated NESG1 in nasopharyngeal carcinoma: its potential role and preliminarily functional mechanism. Int J Cancer (2010) 1.11
Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys (2002) 1.11
Radiation-induced reductions in regional lung perfusion: 0.1-12 year data from a prospective clinical study. Int J Radiat Oncol Biol Phys (2009) 1.10
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist (2010) 1.10
Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer (2007) 1.09